TY - JOUR
T1 - Pneumococcal antibodies in a child with type 14 pneumococcal conjugate vaccine failure
AU - O'Brien, Katherine L.
AU - Moïsi, Jennifer
AU - Romero-Steiner, Sandra
AU - Holder, Patricia
AU - Carlone, George M.
AU - Reid, Raymond
AU - Santosham, Mathuram
N1 - Funding Information:
The authors wish to acknowledge the dedicated work of the nurses, research program assistants and other staff of the Center for American Indian Health. They also wish to recognize the efforts of the families who participated in this study. The views expressed here are those of the authors and do not necessarily reflect those of the Indian Health Service. The American Indian PnCRM7 Efficacy Trial was funded by Wyeth Vaccines, the National Institutes of Health, the World Health Organization and the Centers for Disease Control and Prevention.
PY - 2009/3/13
Y1 - 2009/3/13
N2 - We measured the concentration, opsonic activity, and avidity of serotype-specific serum antibodies in a pneumococcal conjugate vaccine (PnCRM7) efficacy trial participant who contracted serotype 14 pneumococcal bacteremia following dose 3 of PnCRM7. Controls included 18 PnCRM7- and 10 MnCC-vaccinated children without invasive pneumococcal disease (IPD). The child with vaccine failure had 4.98 mcg/mL of serotype 14 antibodies 10 days before disease onset; these antibodies had greater opsonic activity and lower avidity than those of control PnCRM7 recipients. The child had no booster response to a fourth dose of PnCRM7 for most vaccine serotypes. We conclude that antibody concentration, functional activity and avidity do not predict individual protection against IPD, and immunological correlates of protection are only useful at the population level.
AB - We measured the concentration, opsonic activity, and avidity of serotype-specific serum antibodies in a pneumococcal conjugate vaccine (PnCRM7) efficacy trial participant who contracted serotype 14 pneumococcal bacteremia following dose 3 of PnCRM7. Controls included 18 PnCRM7- and 10 MnCC-vaccinated children without invasive pneumococcal disease (IPD). The child with vaccine failure had 4.98 mcg/mL of serotype 14 antibodies 10 days before disease onset; these antibodies had greater opsonic activity and lower avidity than those of control PnCRM7 recipients. The child had no booster response to a fourth dose of PnCRM7 for most vaccine serotypes. We conclude that antibody concentration, functional activity and avidity do not predict individual protection against IPD, and immunological correlates of protection are only useful at the population level.
KW - Immunogenicity
KW - Pneumococcal conjugate vaccine
KW - Streptococcus pneumoniae
KW - Vaccine failure
UR - http://www.scopus.com/inward/record.url?scp=61449245397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=61449245397&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2008.12.060
DO - 10.1016/j.vaccine.2008.12.060
M3 - Article
C2 - 19171175
AN - SCOPUS:61449245397
SN - 0264-410X
VL - 27
SP - 1863
EP - 1868
JO - Vaccine
JF - Vaccine
IS - 12
ER -